rine concentrations of vilanterol after inhaled administration of vilanterol/fluticasone furoate: Defining a urine threshold and decision limit for vilanterol in doping control analysis

Center for Aktiv Sundhed, Rigshospitalet0 个研究点目标入组 26 人开始时间: 2018年7月3日最近更新: 2021年4月5日

适应症

试验速览

暂无简介。

•Included subjects are:
•- 18 - 39 years
•- Able to use an inhalation device
•- Active at least 5 hours a week
•- VO2-max classified as high or very high measured during incremental test to exhaustion during the screening visit
•- Male or non-pregnant female
•- Females of childbearing potential has to use one or more methods for contraception in order to be included: vasectomised partner, bilateral tubal occlusion, sexual abstinence, intrauterine device or hormonal contraception.
•- Females who are considered to have no childbearing potential are: bilateral tubal ligation, bilateral oophorectomy, complete hysterectomy, postmenopausal defined as 12 months with no menses without an alternative Medical cause.
•- Non-smokers
•- No daily use of prescribed medicine
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 26
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Diagnosis of Heart, pulmonary (including asthma GINA 2-5), intestinal and renal diseases
•- Allergy towards active drug or any substances used in the drug
•- Non-compliance with the protocol

发起方

Center for Aktiv Sundhed, Rigshospitalet